AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone847-932-7900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$33.27 billion
Profitability
Miscellaneous
Employees30,000
Next Earnings Date4/23/2020 (Estimated)
OptionableOptionable
AbbVie (NYSE:ABBV) Frequently Asked Questions
What is AbbVie's stock symbol?
AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."
How often does AbbVie pay dividends? What is the dividend yield for AbbVie?
AbbVie declared a quarterly dividend on Thursday, February 20th. Investors of record on Wednesday, April 15th will be given a dividend of $1.18 per share on Friday, May 15th. This represents a $4.72 dividend on an annualized basis and a yield of 5.65%. The ex-dividend date is Tuesday, April 14th. View AbbVie's Dividend History.
How will AbbVie's stock buyback program work?
AbbVie declared that its board has authorized a stock repurchase plan on Thursday, December 13th 2018, which allows the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 3.8% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's management believes its shares are undervalued.
How were AbbVie's earnings last quarter?
AbbVie Inc (NYSE:ABBV) released its quarterly earnings data on Friday, February, 7th. The company reported $2.21 earnings per share for the quarter, topping the Zacks' consensus estimate of $2.19 by $0.02. The company had revenue of $8.70 billion for the quarter, compared to analysts' expectations of $8.68 billion. AbbVie had a net margin of 23.69% and a negative return on equity of 162.54%. The firm's quarterly revenue was up 4.8% compared to the same quarter last year. During the same period last year, the firm earned $1.90 EPS. View AbbVie's Earnings History.
When is AbbVie's next earnings date?
What guidance has AbbVie issued on next quarter's earnings?
AbbVie updated its FY20 earnings guidance on Friday, February, 7th. The company provided earnings per share (EPS) guidance of $9.61-9.71 for the period, compared to the Thomson Reuters consensus EPS estimate of $9.78.
What price target have analysts set for ABBV?
15 analysts have issued 1-year price targets for AbbVie's shares. Their forecasts range from $66.61 to $105.00. On average, they expect AbbVie's share price to reach $89.89 in the next year. This suggests a possible upside of 7.5% from the stock's current price. View Analyst Price Targets for AbbVie.
What is the consensus analysts' recommendation for AbbVie?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 6 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AbbVie.
Has AbbVie been receiving favorable news coverage?
Headlines about ABBV stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. AbbVie earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for AbbVie.
Who are some of AbbVie's key competitors?
Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Perrigo (PRGO), The Medicines (MDCO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT).
What other stocks do shareholders of AbbVie own?
Who are AbbVie's key executives?
AbbVie's management team includes the folowing people:
- Mr. Richard A. Gonzalez, Chairman & CEO (Age 65)
- Dr. Michael E. Severino, Vice Chairman & Pres (Age 53)
- Mr. Robert A. Michael, Sr. VP & CFO (Age 49)
- Mr. William J. Chase, Exec. VP of Fin. & Admin. (Age 51)
- Ms. Laura J. Schumacher, Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. (Age 56)
Who are AbbVie's major shareholders?
AbbVie's stock is owned by a number of of institutional and retail investors. Top institutional investors include Capital Research Global Investors (5.86%), State Street Corp (4.65%), FMR LLC (2.72%), Geode Capital Management LLC (1.65%), Bank of New York Mellon Corp (1.02%) and Renaissance Technologies LLC (0.80%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.
Which major investors are selling AbbVie stock?
ABBV stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Schroder Investment Management Group, Capital International Investors, Skandinaviska Enskilda Banken AB publ , Victory Capital Management Inc., Levin Easterly Partners LLC, Bank of New York Mellon Corp and Bank of Montreal Can. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Brian L Durkin, Laura J Schumacher and Timothy J Richmond. View Insider Buying and Selling for AbbVie.
Which major investors are buying AbbVie stock?
ABBV stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, Janus Henderson Group PLC, Farallon Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., Amundi Pioneer Asset Management Inc., MERIAN GLOBAL INVESTORS UK Ltd and MERIAN GLOBAL INVESTORS UK Ltd. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin and William J Chase. View Insider Buying and Selling for AbbVie.
How do I buy shares of AbbVie?
Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is AbbVie's stock price today?
One share of ABBV stock can currently be purchased for approximately $83.59.
How big of a company is AbbVie?
AbbVie has a market capitalization of $123.65 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.View Additional Information About AbbVie.
What is AbbVie's official website?
How can I contact AbbVie?
AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.
MarketBeat Community Rating for AbbVie (NYSE ABBV)
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe ABBV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABBV will underperform the S&P 500 over the long term. You may vote once every thirty days.
